Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

1.9K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
1.9K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

398
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
398
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

500
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
500
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

510
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
510
Factors affecting Blood pressure01:28

Factors affecting Blood pressure

3.0K
Several physiological and lifestyle factors influence blood pressure (BP). Understanding these factors is crucial as they are significant in patient education and blood pressure management.
Physiological Factors:
3.0K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

606
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
606

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Central Systolic Blood Pressure and Left Ventricular Mass: Findings From the International 24-Hour Aortic Blood Pressure Consortium.

Journal of the American Heart Association·2026
Same author

Cardiovascular Grand Challenge: a new funding initiative by the British Heart Foundation.

European heart journal·2026
Same author

Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals.

Nature medicine·2026
Same author

Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis.

Diabetes, obesity & metabolism·2026
Same author

Hierarchical Composite End Points: The Future of Randomized Trials of Kidney Disease?

Clinical journal of the American Society of Nephrology : CJASN·2026
Same author

Lifetime benefits of finerenone on cardiorenal morbidity and mortality in chronic kidney disease and type 2 diabetes: a pooled analysis of FIDELIO-DKD and FIGARO-DKD trials.

European heart journal·2026
Same journal

Brain Iron in Nucleus Accumbens and Cognitive Function in Preeclampsia.

Hypertension (Dallas, Tex. : 1979)·2026
Same journal

Hypertension Treatment Intentions: A Health Belief Model Analysis.

Hypertension (Dallas, Tex. : 1979)·2026
Same journal

Changes in Retinal Microvasculature During Healthy Pregnancy Measured by AO.

Hypertension (Dallas, Tex. : 1979)·2026
Same journal

Longitudinal Maternal IgG and IgA Glycosylation Profiles in Pregnancy Reveal Early Immune Alterations in Placenta-Related Complications: The Rotterdam Periconception Cohort.

Hypertension (Dallas, Tex. : 1979)·2026
Same journal

Blood Pressure Variability and Outcomes Across Antihypertensive Regimens.

Hypertension (Dallas, Tex. : 1979)·2026
Same journal

Rural Health and Health Disparities in Hypertension Management: A Scientific Statement From the American Heart Association.

Hypertension (Dallas, Tex. : 1979)·2026
See all related articles

Related Experiment Video

Updated: Jun 13, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.1K

Resistant Hypertension and Mortality: An Observational Cohort Study.

Alejandro de la Sierra1, Luis M Ruilope2, Natalie Staplin3

  • 1Department of Internal Medicine, Hospital Mutua Terrassa, University of Barcelona, Terrassa, Spain (A.d.l.S.).

Hypertension (Dallas, Tex. : 1979)
|September 9, 2024
PubMed
Summary
This summary is machine-generated.

Resistant hypertension, especially when confirmed by ambulatory blood pressure monitoring (ABPM), significantly increases the risk of all-cause and cardiovascular death compared to controlled hypertension.

Keywords:
blood pressureblood pressure monitoring, ambulatoryhypertensionmortalitypopulation

More Related Videos

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

685
Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension
09:40

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension

Published on: April 11, 2016

20.9K

Related Experiment Videos

Last Updated: Jun 13, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.1K
Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

685
Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension
09:40

Hemodynamic Characterization of Rodent Models of Pulmonary Arterial Hypertension

Published on: April 11, 2016

20.9K

Area of Science:

  • Cardiology
  • Hypertension Research
  • Clinical Outcomes

Background:

  • Resistant hypertension (RH) is defined as elevated blood pressure (BP) despite three antihypertensive agents.
  • Ambulatory BP monitoring (ABPM) can distinguish true RH from white-coat RH.
  • The prognostic implications of ABPM-confirmed RH versus white-coat RH require further clarification.

Purpose of the Study:

  • To compare all-cause and cardiovascular mortality risks between patients with controlled hypertension and resistant hypertension.
  • To evaluate the differential mortality risks between ABPM-confirmed resistant hypertension and white-coat resistant hypertension.

Main Methods:

  • A cohort study involving 8146 patients with controlled hypertension and 8577 with resistant hypertension.
  • Patients were categorized into white-coat RH (n=3289) and ABPM-confirmed RH (n=5288) groups.
  • Cox models were used to compare all-cause and cardiovascular mortality after adjusting for confounders over a median follow-up of 9.7 years.

Main Results:

  • Resistant hypertension was associated with increased all-cause (HR 1.21) and cardiovascular mortality (HR 1.33) versus controlled hypertension.
  • ABPM-confirmed RH showed higher risks of all-cause (HR 1.45) and cardiovascular mortality (HR 1.68) compared to white-coat RH.
  • Only ABPM-confirmed RH, not white-coat RH, was linked to significantly increased mortality compared to controlled hypertension.

Conclusions:

  • ABPM-confirmed resistant hypertension carries a significantly higher risk of mortality than white-coat resistant hypertension.
  • Accurate diagnosis of resistant hypertension using ABPM is crucial for risk stratification and management.